Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bone Marrow Aspirate Concentrate (BMAC) is an autologous biological therapy produced by concentrating a patient's bone marrow aspirate, typically harvested from the iliac crest. The concentration process, usually performed via centrifugation at the point of care, yields a heterogeneous population of cells including mesenchymal stem cells (MSCs), hematopoietic stem cells, and platelets. BMAC is rich in growth factors such as transforming growth factor-beta (TGF-β) and platelet-derived growth factor (PDGF), as well as anti-inflammatory cytokines like interleukin-1 receptor antagonist (IL-1Ra). In the treatment of post-traumatic osteoarthritis (PTOA) of the knee, BMAC is administered via intra-articular injection to modulate the joint's inflammatory environment, promote chondrogenic differentiation, and support the repair of damaged cartilage and meniscal tissues. The Affinity Health Research Institute is specifically investigating BMAC as a standalone intervention and as a component of the ERIPTO protocol to evaluate its clinical and radiographic impact on knee PTOA progression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bone Marrow Aspirate Concentrate (Affinity Health Research Institute).